Dexiang Zhu, Jie Wang, and Li Ren contributed equally to this work.
Article first published online: 17 DEC 2012
Copyright © 2012 Wiley Periodicals, Inc.
Journal of Cellular Biochemistry
Volume 114, Issue 2, pages 448–455, February 2013
How to Cite
Zhu, D., Wang, J., Ren, L., Li, Y., Xu, B., Wei, Y., Zhong, Y., Yu, X., Zhai, S., Xu, J. and Qin, X. (2013), Serum proteomic profiling for the early diagnosis of colorectal cancer. J. Cell. Biochem., 114: 448–455. doi: 10.1002/jcb.24384
Conflicts of interest: none to declare.
- Issue published online: 17 DEC 2012
- Article first published online: 17 DEC 2012
- Accepted manuscript online: 7 SEP 2012 07:55AM EST
- Manuscript Accepted: 30 AUG 2012
- Manuscript Received: 21 JUL 2012
- Ministry of Health. Grant Number: Projects from 2010 to 2012
- National Natural Science Foundation. Grant Numbers: 30973416, 81101566
- Talent Fund of Shanghai Municipal Health Bureau. Grant Numbers: XYQ2011017, XBR2011031
- SERUM PEPTIDES;
- COLORECTAL CANCER;
- MALDI-TOF MS
No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Magnetic bead-based fractionation coupled with MALDI-TOF MS was used to screen serum samples from CRC patients, healthy controls, and other cancer patients. A diagnostic model with five proteomic features (m/z 1778.97, 1866.16, 1934.65, 2022.46, and 4588.53) was generated using Fisher algorithm with best performance. The Fisher-based model could discriminate CRC patients from the controls with 100% (46/46) sensitivity and 100% (35/35) specificity in the training set, 95.6% (43/45) sensitivity and 83.3% (35/42) specificity in the test set. We further validated the model with 94.4% (254/269) sensitivity and 75.5% (83/110) specificity in the external independent group. In other cancers group, the Fisher-based model classified 25 of 46 samples (54.3%) as positive and the other 21 as negative. With FT-ICR-MS, the proteomic features of m/z 1778.97, 1866.16, 1934.65, and 2022.46, of which intensities decreased significantly in CRC, were identified as fragments of complement C3f. Therefore, the Fisher-based model containing five proteomic features was able to effectively differentiate CRC patients from healthy controls and other cancers with a high sensitivity and specificity, and may be CRC-specific. Serum complement C3f, which was significantly decreased in CRC group, may be relevant to the incidence of CRC. J. Cell. Biochem. 114: 448–455, 2013. © 2012 Wiley Periodicals, Inc.